Back

Hugel cuts target 15% as U.S. sales overhaul weighs on Q3 earnings

Verifying
  • Hugel is shifting U.S. botulinum toxin sales from Benev distribution toward direct sales.
  • Daishin Securities cut Hugel's target price 15% to 340,000 won.
  • Daishin Securities forecasts 2028 operating profit of 331.2 billion won.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.